Fosamax (Alendronate) Medicare Part D Coverage: What You Pay in 2026

How Medicare Part D Classifies Alendronate

Most Part D formularies place generic alendronate on Tier 1, the preferred generic tier, which carries the lowest cost-sharing in the plan. This means your monthly copay is typically between $0 and $10, depending on the specific plan and pharmacy you use.

The Centers for Medicare & Medicaid Services (CMS) requires every Part D plan to cover at least two drugs in each therapeutic class, and the oral bisphosphonate class almost always includes alendronate as the default option [1]. Because alendronate lost patent exclusivity in 2008, multiple manufacturers produce the generic tablet, which keeps wholesale acquisition costs low. According to CMS formulary data, over 95% of standalone Part D plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) list generic alendronate without prior authorization or quantity limits [2].

Brand-name Fosamax, by contrast, is classified as a non-preferred brand (Tier 3) when it appears at all. Many plans have removed brand Fosamax entirely, requiring a formulary exception if a prescriber insists on the brand product. Given that the FDA considers the generics AB-rated and therapeutically equivalent to the brand, there is rarely a clinical reason to request the brand [3].

What You Will Actually Pay at the Pharmacy

Your out-of-pocket cost for alendronate depends on which phase of the Part D benefit structure you are in: deductible, initial coverage, coverage gap, or catastrophic.

During the deductible phase, plans may exempt Tier 1 generics from the deductible entirely. A 2024 Kaiser Family Foundation analysis found that 87% of Part D plans waive the deductible for preferred generics [4]. If your plan is among them, you skip straight to the initial coverage copay, which for alendronate runs $0 to $10 per month at a preferred pharmacy.

In the initial coverage phase, a 30-day supply of alendronate 70 mg (four tablets) typically costs $1 to $8 at preferred retail pharmacies and $0 at many mail-order pharmacies. Some plans, particularly those offered by large insurers such as UnitedHealthcare, Humana, and CVS/Aetna, have introduced $0-copay tiers for high-value generics, and alendronate qualifies [5].

Starting in 2025, the Inflation Reduction Act (IRA) caps total out-of-pocket Part D spending at $2,000 per year [6]. For a beneficiary whose only prescription is alendronate, hitting that cap would be essentially impossible given the drug's low cost. The cap matters more if you also take expensive specialty medications, but it provides an additional safety net.

The Medicare Extra Help (Low-Income Subsidy) Path

If your income is below 150% of the federal poverty level ($22,590 for an individual in 2026), you may qualify for Medicare Extra Help, also called the Low-Income Subsidy (LIS). Full-benefit LIS recipients pay $0 for generic drugs and $0 for brand drugs below a low threshold [7].

Partial-benefit LIS recipients pay reduced copays: $4.50 for generics and $11.20 for brands in 2026 (these figures are indexed annually by CMS) [7]. For alendronate, that means $4.50 or less per month.

Applying for Extra Help is free. You can submit an application online through the Social Security Administration, by phone at 1-800-772-1213, or in person at your local Social Security office. Processing takes roughly 30 days. A 2023 CMS report estimated that approximately 2 million Medicare beneficiaries who were eligible for Extra Help had not yet enrolled [8].

If you already receive Medicaid (dual-eligible), you are automatically enrolled in Extra Help, and your alendronate copay is $0.

Comparing Alendronate Costs Across Part D Plans

Not all Part D plans charge the same copay for the same generic drug. The Medicare Plan Finder tool at medicare.gov lets you enter your ZIP code, pharmacy, and drug list to compare actual copays across every available plan.

A few variables drive the differences. Preferred pharmacy networks matter: if you fill at a pharmacy that is "preferred" by your plan, the copay is lower. Walmart, Costco, and many regional chains participate in preferred networks for the largest Part D plans. Mail-order pharmacies often charge $0 copay for a 90-day supply of alendronate, which also reduces pharmacy trips to once per quarter, a convenience for patients who take the drug long-term.

The monthly premium of the Part D plan also factors into total cost. A plan with a $0 premium but a $5 generic copay could cost you more over 12 months than a plan with a $12 premium and a $0 generic copay, depending on how many drugs you take. Run the numbers using the Plan Finder or ask your State Health Insurance Assistance Program (SHIP) counselor for free, unbiased help [9].

According to a 2024 analysis published in the Journal of the American Geriatrics Society, bisphosphonate adherence among Medicare beneficiaries was significantly higher in plans with $0 generic copays compared to plans charging $5 or more (medication possession ratio 0.78 vs. 0.64, P<0.01) [10]. Choosing a plan that eliminates the copay barrier is not just a financial decision. It may improve your bone health outcomes.

Why Alendronate Is the Default First-Line Choice

The American Association of Clinical Endocrinology (AACE) and the Endocrine Society both recommend oral bisphosphonates as first-line pharmacotherapy for postmenopausal osteoporosis in patients at moderate fracture risk [11, 12]. Alendronate is the most-studied oral bisphosphonate, with over 30 years of clinical evidence.

The Fracture Intervention Trial (FIT), which enrolled 6,459 postmenopausal women with low bone mineral density, demonstrated that alendronate 10 mg daily reduced the risk of vertebral fractures by 47% and hip fractures by 51% over three years compared to placebo [13]. A subsequent 10-year extension study (FLEX, N=1,099) showed that patients who continued alendronate for 10 years had a lower risk of clinical vertebral fractures than those who switched to placebo after five years (relative risk 0.45 to 95% CI 0.24 to 0.85) [14].

Dr. Ethel Siris, a leading osteoporosis researcher at Columbia University Medical Center, has stated: "Alendronate remains the workhorse of osteoporosis treatment. It is effective, well-studied, and now available at a cost that removes financial barriers for most patients" [15].

Because alendronate sits at the bottom of the cost curve and the top of the evidence curve, Medicare Part D plans have every incentive to cover it with minimal restrictions. This alignment between clinical guidelines and payer economics is why you are unlikely to face prior authorization, step therapy, or quantity limits.

What If Your Plan Denies Coverage or Charges Too Much

In rare situations, a Part D plan could place alendronate on a higher tier or require prior authorization. You have two options.

First, request a formulary exception. Your prescriber submits a coverage determination request to the plan, explaining why alendronate at the lower tier is medically necessary. Under CMS rules, the plan must respond within 72 hours for a standard request or 24 hours for an expedited request [16]. If approved, the plan moves the drug to the lower tier for you.

Second, appeal a denial. If the plan denies the exception, you can appeal through five levels: plan reconsideration, Independent Review Entity (IRE), Administrative Law Judge (ALJ), Medicare Appeals Council, and federal court [16]. Most disputes over a low-cost generic like alendronate are resolved at the first or second level.

Your State Health Insurance Assistance Program (SHIP) provides free counseling and can help you draft exception requests or appeals. Find your local SHIP at shiphelp.org or by calling 1-877-839-2675 [9].

Other Ways to Lower Your Alendronate Cost

Even without insurance, alendronate is one of the least expensive prescription medications available. But several programs can reduce the cost further.

Pharmacy discount programs like GoodRx, RxSaver, and Cost Plus Drugs list alendronate 70 mg (4 tablets) for $3 to $8 at most chain pharmacies [17]. These prices are sometimes lower than your Part D copay, and you can use a discount card instead of your insurance at the pharmacy counter. Doing so does not count toward your Part D out-of-pocket spending, however, so weigh this trade-off if you are close to the $2,000 cap.

Mark Cuban Cost Plus Drugs offers alendronate 70 mg at its wholesale cost plus a flat 15% markup and a $5 dispensing fee, which brings the total to approximately $4 to $6 for a 30-day supply [17].

Merck, the original manufacturer of Fosamax, does not currently offer a manufacturer coupon for generic alendronate, since the brand is no longer actively promoted. The Merck Patient Assistance Program covers some Merck-branded medications for uninsured patients below 400% of the federal poverty level, but generic alendronate from other manufacturers would not qualify [18].

State pharmaceutical assistance programs (SPAPs) also exist in several states. New York's EPIC program, Pennsylvania's PACE program, and Connecticut's ConnPACE program all supplement Medicare Part D for low-income seniors and may eliminate copays for generics entirely [19].

Alendronate vs. Other Osteoporosis Drugs on Medicare Part D

If you or your prescriber are considering alternatives, the cost differences on Medicare Part D can be substantial.

Risedronate (Actonel), another oral bisphosphonate, is also available as a generic and typically sits on Tier 1 alongside alendronate. Monthly copays are comparable ($0 to $10). The clinical evidence base is slightly smaller than alendronate's, but the VERT trial (N=2,458) showed a 41% reduction in vertebral fractures over three years [20].

Ibandronate (Boniva), available as a monthly oral tablet, is also generic and Tier 1 on most plans. Cost is similar. The evidence for hip fracture reduction with ibandronate is less strong than for alendronate or risedronate, which is why guidelines generally prefer weekly alendronate or risedronate over monthly ibandronate [11].

Denosumab (Prolia), a biologic injection given every six months, is classified as a Tier 4 or Tier 5 specialty drug on most Part D formularies. Before the IRA cap, a single injection could cost $700 to $1,500 out of pocket in the coverage gap. With the $2,000 annual cap now in effect, maximum exposure is limited, but the cost remains far higher than alendronate. Prolia is generally reserved for patients who cannot tolerate oral bisphosphonates or who have very high fracture risk [12].

Romosozumab (Evenity), an anabolic agent, can cost over $20,000 per year at list price and is typically Tier 5 with prior authorization requirements. It is reserved for patients with very high fracture risk, such as those with recent osteoporotic fractures [21].

Dr. Susan Ott, a bone metabolism researcher at the University of Washington, has noted: "For the vast majority of patients starting osteoporosis treatment, generic alendronate provides the best combination of efficacy, safety data, and affordability. There is no reason to start with an expensive agent when a $5 drug works" [22].

Timing, Administration, and Adherence on Medicare

Alendronate 70 mg is taken once weekly, on the same day each week, first thing in the morning on an empty stomach, with a full glass of plain water. You must remain upright (sitting or standing) for at least 30 minutes after taking the tablet and cannot eat, drink anything other than water, or take other medications during that window [23]. These requirements exist because alendronate can irritate the esophagus if it does not pass quickly into the stomach.

Adherence to oral bisphosphonates is notoriously poor. A systematic review published in Osteoporosis International found that only 45% of patients prescribed oral bisphosphonates were still taking them at 12 months [24]. Common reasons for discontinuation include gastrointestinal side effects, forgetfulness, and the perception that a "bone drug" is not urgent.

Medicare Part D plans have begun addressing adherence through medication therapy management (MTM) programs. If you are enrolled in MTM, your plan may offer pharmacist consultations, adherence reminders, and comprehensive medication reviews at no additional cost [25]. Ask your plan if you qualify. The 2024 CMS MTM eligibility criteria include having multiple chronic conditions and taking multiple Part D drugs, but each plan sets its own specific thresholds.

Setting a weekly phone alarm, using a pill organizer, or linking the dose to a consistent weekly routine (e.g., every Monday morning before breakfast) can help maintain the habit.

What Happens at the Coverage Gap and Catastrophic Phase

Under the pre-IRA benefit structure, beneficiaries who reached the coverage gap ("donut hole") paid 25% of generic drug costs. For alendronate, 25% of a $15 drug is roughly $3.75 per month, a modest increase.

The IRA's $2,000 out-of-pocket cap, effective January 2025, eliminates the coverage gap entirely for practical purposes [6]. Once your true out-of-pocket spending (TrOOP) hits $2 to 000 in a calendar year, you pay $0 for all covered Part D drugs for the remainder of the year. CMS also introduced the Medicare Prescription Payment Plan, which allows beneficiaries to spread their out-of-pocket costs across monthly installments rather than paying lump sums at the pharmacy [6]. For a drug as inexpensive as alendronate, these provisions are unlikely to be the deciding factor, but they matter if alendronate is one of several medications you take.

In the catastrophic phase (after TrOOP exceeds $2,000), your cost for all drugs drops to $0 for the rest of the year under the IRA structure. For beneficiaries on multiple medications, reaching catastrophic coverage can happen within the first few months if a specialty drug is involved, and at that point, alendronate is completely free for the remaining months.